Long-term safety and efficacy of telmisartan/amlodipine single pill combination in the treatment of hypertension

Scott S Billecke
Pamela A Marcovitz
Beaumont Health System, Ministrelli Women’s Heart Center, Royal Oak, MI, USA

Abstract: The use of multiple drug regimens is increasingly recognized as a tacit requirement for the management of hypertension, a necessity fueled in part by rising rates of metabolic syndrome and diabetes. By targeting complementary pathways, combinations of antihypertensive drugs can be applied to provide effective blood pressure control while minimizing side effects and reducing exposure to high doses of individual medications. In addition, combination therapies, including angiotensin converting enzyme (ACE) inhibitors and calcium channel blockers (CCBs), have the added benefit of reducing cardiovascular mortality and morbidity over other dual therapies while providing equivalent blood pressure control. It is possible that angiotensin receptor blockers (ARBs), which unlike ACE inhibitors are minimally affected by upregulation of alternative pathways for angiotensin II accumulation following long-term treatment, would also provide such outcome benefits. At issue, however, is maintaining patient compliance, as adding medications is known to reduce adherence to treatment regimens. The purpose of this review is to summarize existing trial data for the long-term safety and efficacy of a recent addition to the armamentarium of dual-antihypertensive therapeutic options, the telmisartan/amlodipine single pill combination. The areas where long-term data are lacking, notably clinical information regarding minorities and women, will also be discussed.

Keywords: Angiotensin receptor blocker, antihypertensive, calcium channel blocker, clinical trial, combination pill

Hypertension remains the most prevalent cardiovascular disease (CVD) risk factor and is present in ever-growing numbers worldwide.1,2 In the United States hypertension affects over 30% of adults or approximately 76,400,000 (2008 data) men and women age ≥ 20 years. Data from the National Health and Nutrition Examination Survey indicate that approximately 8% of adults in the United States have undiagnosed hypertension, and of those diagnosed only three-quarters use antihypertensive medications. Among those taking medication, blood pressure (BP) is controlled in only half.3 The societal and financial burden of hypertension is not likely to reverse soon as projections suggest a 10% increase in hypertension prevalence by the year 2030.4 These statistics are especially troubling when one considers the consequences of hypertension; elevated BP (>140/90 mmHg) preceeds myocardial infarction (MI), stroke, or congestive heart failure in ≥69% of cases.5 Improved awareness and effective treatments, therefore, remain foremost goals for the patient and physician.

The cardiovascular risk associated with high BP and its prevalence is influenced by numerous factors, including race, gender, and underlying comorbidities. In the United States, black communities are characterized by a high incidence of hypertension, with African-American adults displaying an occurrence rate of 41.4% compared with 28.1%
fewer physician visits and hospitalizations for cardiovascular profiles are dissimilar. Two drugs minimizes side effects, provided that the side-effect with higher dose monotherapy, benefits beyond improved compliance. Blood pressure control which can improve compliance by as much as 25%.

The number of medications associated with the ACE inhibitor/CCB combination, likely via effects on the renin–angiotensin system (RAS). Of note, because patients initiated on ARB therapy exhibit greater maintenance of treatment than for other antihypertensives, use of an ARB in place of an ACE in this combination may further improve compliance and, by extension, outcomes. While it is unclear whether ARB/amlodipine combinations provide similar outcome benefits, a 4-year prospective study is currently underway in China to explore the potential cardiovascular mortality and morbidity benefits of ARB + amlodipine treatment versus diuretic + amlodipine. Results from this study should provide additional insights regarding the effectiveness of these antihypertensive drug combinations in BP control and hard clinical endpoints.

One recent dual antihypertensive single pill combination with promising clinical impact is Twynsta® (Boehringer Ingelheim, Ingelheim, Germany), a telmisartan/amlodipine combination pill approved by the US Food and Drug Administration in 2009 and the European Medicines Agency the following year. Amlodipine (Norvasc®; Pfizer Pharmaceuticals, New York, NY, USA), a CCB in the dihydropyridine class, has been used extensively since its approval in 1993, whereas telmisartan (Micardis®, Boehringer Ingelheim, Ingelheim, Germany) has a shorter clinical history, having been approved in 2000. Each antihypertensive drug has been combined with multiple other antihypertensive medications into a single pill, but this combination is unique in that it combines the only ARB currently indicated for the prevention of CVD progression (telmisartan) with one of the most broadly used and well-studied CCBs (amlodipine). The clinical safety and efficacy of both telmisartan and amlodipine monotherapy for hypertension have been reviewed extensively elsewhere. The purpose of this review is to briefly describe the complementary mechanisms of action of telmisartan and amlodipine and detail the long-term safety and efficacy profile of the telmisartan/amlodipine combination pill. An emphasis will
also be placed on populations underrepresented in these trials and the potential implications of this knowledge deficit.

**Pharmacokinetics and pharmacodynamics of telmisartan and amlodipine**

Telmisartan and amlodipine reduce BP through complementary mechanisms that are synergistic in their BP-lowering effects; their individual mechanisms of action have been extensively reviewed elsewhere. The telmisartan chemical structure possesses the biphenyl-tetrazol and imidazol groups common to all ARBs (Figure 1). Telmisartan is highly selective for the angiotensin II type 1 receptor (AT1) where it blocks the deleterious effects of ang II, which include vasoconstriction; activation of the protein kinase C, NADPH oxidase, Janus kinase/signal transducer and activator of transcription cascade; release of catecholamines from the adrenal medulla; aldosterone secretion; and cell proliferation. In addition, at higher but still clinically relevant doses, telmisartan acts as a partial agonist of peroxisome proliferator-activated receptor γ and as such produces beneficial effects in patients by improving glucose intolerance, insulin resistance, and lipid metabolism. Amlodipine, in contrast, is a dihydropyridine CCB that binds to a transmembrane site on L-type calcium channels within cardiac and smooth muscle cells, thereby inhibiting calcium ion influx with downstream disruption of myosin–actin interactions to reduce muscle contractility. The net effect of amlodipine on the vasculature is vasodilation resulting in lower peripheral resistance and a reduced BP.

Individually, telmisartan and amlodipine exhibit different pharmacokinetic profiles with regard to rate of absorption, volume of distribution, and metabolism. Of the ARBs marketed for hypertension, telmisartan is the most lipophilic, a characteristic contributing to it having the longest half-life, highest AT1 receptor affinity, and largest volume of distribution among the ARBs. The bioavailability of telmisartan is approximately 45% to 50% and that of amlodipine is between 64% and 90%. Amlodipine is extensively bound to plasma proteins (93%) as is telmisartan (>99%). Steady-state blood levels of amlodipine are achieved in 7 to 8 days and in 5 to 7 days for telmisartan.

Both telmisartan and amlodipine have relatively long half-lives, from 20 to 30 hours for the former and 44 hours or more for the latter. Telmisartan does not undergo significant first-pass metabolism, and the majority (approximately 97%) is eliminated by biliary-fecal excretion as the parent compound, although a small percentage of the drug undergoes glucuronidation. Amlodipine, in contrast, is converted to inactive metabolites hepatically with approximately 60% excreted as metabolized products and 10% as parent compound in urine. The effect of telmisartan and amlodipine coadministration on the other’s pharmacokinetic profile is reportedly equivalent to the individually administered compounds, with the two-sided 90% confidence intervals for all pharmacokinetic endpoints residing within the standard bioequivalence acceptance interval (80% to 125%). Taking telmisartan/amlopidine with a high-fat meal can reduce telmisartan plasma concentrations by about 25% and increase amlodipine slightly compared with fasting conditions.

A recently appreciated aspect of RAS inhibition is the presence of alternative pathways capable of producing ang II without any appreciable contribution by ACE. Most antihypertensive agents increase plasma renin activity leading to accumulation of ang I, which in turn helps facilitate metabolism of ang I into ang II via alternative pathways, most notably chymase activity in cardiac monocytes, vascular smooth muscle cells, and renal mesangial cells; this so-called “ACE escape” can result in a diminished response to drug over time. In addition, the phenomenon of aldosterone breakthrough has been reported for both ACE inhibitors and ARBs, representing another deleterious compensatory mechanism exposed by these medication classes.

RAS inhibition may also have an unexpected effect on a novel counterregulatory and cardioprotective pathway involving the peptide angiotensin (1-7), a product of...
ang I or ang II cleavage produced by numerous enzymes, including prolyl-endopeptidase, prolyl-carboxypeptidase, neutral-endopeptidase, and ACE2.63–65 Angiotensin (1-7) is a vasodilator that targets the G protein-coupled Mas receptor both peripherally and centrally.66 Activated Mas receptors are thought to interact with ang II receptors as a physiologic antagonist and increase nitric oxide and prostaglandin release resulting in vasodilation, reduced fibrosis, diminished cardiac hypertrophy, and a decrease in cell proliferation.67 Both ACE inhibitors and ARBs have been shown to increase plasma ang (1-7).68,69 and a preclinical study showed that telmisartan can upregulate ACE2 and the ang (1-7) receptor in a dilated cardiomyopathy model,70 suggesting that the mechanisms yielding their clinical benefits may go beyond their effects on the traditional RAS pathway.

**Phase III clinical studies**

Although reports on the safety and efficacy of telmisartan/amlodipine combination pill therapy are available from several short-term trials, in this review we focus on long-term studies, specifically those evaluating telmisartan/amlodipine safety and efficacy over 6 months or more. Two such studies were extensions of prior trials entitled Telmisartan plus Amlodipine Study–Amlodipine 5 mg and 10 mg (TEAMSTA-5 and TEAMSTA-10) that collectively followed 1814 patients (40% women) randomized to telmisartan 40 mg/amlodipine 5 mg (T40/A5), T80/A5 (TEAMSTA-5), T40/A10, or T80/A10 (TEAMSTA-10) with further delineations based on add-on therapy or uptitration to a higher telmisartan dose.71 A third long-term trial of 56 weeks duration with results posted on ClinicalTrials.gov (NCT00618774) and the manufacturer’s web site enrolled 259 nonresponders to T40/A5 or A5 treatment (ie, SBP and DBP failed to reach < 140 mmHg and < 90 mmHg, respectively, or decrease by ≥20 mmHg and ≥10 mmHg, respectively) who were identified during the course of two prior studies (ClinicalTrials.gov identifiers NCT00558064 and NCT00550953). A fourth trial spanning 48 weeks was designed to assess the long-term safety of telmisartan/amlodipine combination therapy in 210 hypertensive type 2 diabetics with microalbuminuria whose BP was not controlled (ie, >130/80 mmHg) by T40/A2.5.72

Inclusion and exclusion criteria for the studies were similar with the exception being the study in microalbuminuric type 2 diabetics. This trial enrolled patients whose diabetes was well controlled by diet or oral medication but had two 24-hour urine collections test positive for microalbuminuria (>30 and <300 mg/24hours). Of note, the upper dose of telmisartan used in this study, 160 mg, exceeds the maximum recommended dose for the drug and was selected to observe the effects of high-dose telmisartan/amlodipine on urinary albumin excretion. For the others, participants were typically men and women age ≥18 years with essential hypertension who had either failed to respond to amlodipine 5 mg (ClinicalTrials.gov identifiers NCT00558064 and NCT00614380) or telmisartan 40 mg (NCT00550953). Some common exclusion criteria for the TEAMSTA trials included the following: taking four or more antihypertension medications; secondary hypertension; severe hypertension (SBP ≥200 mmHg or DBP ≥114 mmHg); pregnant or nursing women, or premenopausal women facing potential pregnancy; relevant cardiac arrhythmias; congestive heart failure (New York Heart Association class II–IV); recent MI, stroke, or transient ischemic attack; unstable angina; hyperkalemia or sodium deficiency; angioedema with ARB or ACE inhibitor treatment, or other hypersensitivity to study medications; hepatic and/or renal dysfunction; and chronic use of nonsteroidal anti-inflammatory drugs.

**Telmisartan/amlodipine safety**

Individually, amlodipine and telmisartan produce a generally low incidence of adverse events (AEs) and are well tolerated. The combination may be especially appropriate for those with diabetes and/or metabolic syndrome as these medications do not worsen the metabolic complications associated with their etiology. Most of the trials in which the safety of the telmisartan/amlodipine single pill combination was evaluated were of short duration.53 In an 8-week, placebo-controlled, 4 × 4 factorial design trial, safety was addressed in groups receiving T40/A5, T40/A10, T80/A5, T80/A10, T40, T80, A5, A10, and placebo. AEs occurred within treatment groups at rates similar to those experienced by the placebo group, which had an overall AE incidence of 39% compared with a high of 44% in the T80/A10 group and a low of 33% in the T40/A5 group. The AEs suspected to be drug related were as low as 5.2% (T80) and as high as 19% (T80/A10). The most common AE was peripheral edema, a common side effect of amlodipine attributed to its vasodilatory capacity;42 the incidence of peripheral edema was as high as 18% in the A10 group and 11% in the T80/A10 group. The reduction in peripheral edema observed in the T80/A10 group compared with A10 monotherapy has been observed previously with this drug combination73,74 and with other RAS inhibitors,40,75,76 an effect that further validates choosing such combinations.

Safety information from the longer term trials described previously are shown in Tables 1 and 2 and reflect data from a total of 2283 patients. TEAMSTA study data include
incidence of AEs per 100 patient years as the study designs called for upitration in nonresponders; this same approach was taken for trial NCT00618774, but patient-year data were not available. Among the three trials with AE data delineated by treatment group (Table 1), overall all-cause AEs occurred at incidence rates as low as 12% (T40/A10; TEAMSTA-10), with incidence rates per 100 patient years being ≤51 occurrences. Interestingly, the overall incidence rate was 77% in both arms of the unpublished trial (NCT00618774); however, drug-related AEs did not exceed 8%, or 14 incidences per 100 patient years, for any trial. Discontinuations due to AEs were low among all four studies, occurring at ≤2%. As with the short-term trials, the most common AE was peripheral edema, with increasing incidence among those receiving higher amlodipine doses; a few incidences of dizziness were also reported, and no deaths occurred during the trials.

Of the four long-term trials, only the albuminuria study presented clinical laboratory data (Table 2). Serum potassium levels appeared stable among arms, increasing slightly in those receiving T160/A2.5 but to a lesser extent than has been reported for ACE inhibitors alone or in combination.77

**Telmisartan/amlodipine efficacy**

Efficacy results from three long-term studies are compiled in Table 3. The majority of telmisartan/amlodipine trials utilized DBP control rate (ie, <90 mmHg) as the primary efficacy outcome. This target was reached in ≥76% of participants that did not require maximal upitration and add-on therapy (T80/A5 + drug, TEAMSTA-5) or upitration (T80/A5, trial 1235.16); in these groups, DBP was controlled in 46.4% and 66.7% of recipients, respectively. DBP response rates, defined as DBP < 90 mmHg or decreased by ≥10 mmHg, were no lower than approximately 69%, and SBP response rates (SBP < 140 mmHg or decreased by ≥15 mmHg) were >70% in all groups. Mean BP reductions (Figure 2) indicated significant reductions in all arms, with each improvement ≥12.6/9.5 mmHg. Changes in BP did not typically follow a general dose–response trend within each study; this likely reflected their study designs, which often involved increasing dose or adding therapy in nonresponders as opposed to straight randomization.

None of these long-term studies were designed to compare telmisartan/amlodipine with monotherapy using these or other antihypertensive medications; such trials have generally been limited to 8-week durations.73,78–81 Trials comparing telmisartan/amlodipine with other single pill combinations are likewise few; however, Bekki et al recently described the effect of T80/A5 combination therapy on the BP of 47 patients nonresponsive to amlodipine 5 mg plus valsartan 80 mg or candesartan 8 mg.82 In this study, participants experienced significant decreases in BP, from a baseline of 144/82 to 135/78 mmHg at 12 weeks (P < 0.001). As this was not a randomized controlled study, it is difficult to compare the efficacies of ARB/amlodipine combinations. However, head-to-head trials of ARB monotherapy have suggested that telmisartan provides greater BP control throughout the day, a likely outcome of its long half-life compared with other ARBs.83–85

**Table 1** Safety profile for telmisartan/amlodipine combination therapy: adverse event reporting

<table>
<thead>
<tr>
<th>TEAMSTA-5</th>
<th>TEAMSTA-10</th>
<th>Trial no 1235.16</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>T40/A5</td>
<td>T80/A5</td>
</tr>
<tr>
<td></td>
<td>n = 976</td>
<td>n = 397</td>
</tr>
<tr>
<td>All-cause AEs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>n (%)</td>
<td>381 (39)</td>
<td>201 (51)</td>
</tr>
<tr>
<td></td>
<td>95 per 100 PY</td>
<td>97 per 100 PY</td>
</tr>
<tr>
<td></td>
<td>12 (1.2)</td>
<td>4 (1.0)</td>
</tr>
<tr>
<td>Discontinuations due to AEs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>n (%)</td>
<td>3 per 100 PY</td>
<td>2 per 100 PY</td>
</tr>
<tr>
<td></td>
<td>22 (2.3)</td>
<td>6 (1.5)</td>
</tr>
<tr>
<td>SAE</td>
<td>4 per 100 PY</td>
<td>4 per 100 PY</td>
</tr>
<tr>
<td></td>
<td>51 (5.2)</td>
<td>30 (7.6)</td>
</tr>
<tr>
<td>Study-drug related AE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>n (%)</td>
<td>13 per 100 PY</td>
<td>14 per 100 PY</td>
</tr>
<tr>
<td></td>
<td>23 (2.4)</td>
<td>11 (2.8)</td>
</tr>
<tr>
<td>Treatment-related AE occurring in &gt;1% of patients in any treatment group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peripheral</td>
<td>6 per 100 PY</td>
<td>5 per 100 PY</td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>6 (1.5)</td>
</tr>
<tr>
<td>Edema</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>11 (2.8)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Dizziness</td>
<td>3 per 100 PY</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Notes:** Number of participants (n) represents the number analyzed for the primary efficacy endpoints with the exception of TEAMSTA-10, which analyzed all participants exposed to study drug. An en-dash (–) indicates no data were provided. *Not considered related to study drug.

**Abbreviations:** T, telmisartan; A, amlodipine; TEAMSTA, Telmisartan plus Amlodipine Study–Amlodipine; AE, adverse event; PY, patient years; SAE, serious adverse event.
Table 2 Laboratory and safety data from type 2 diabetics with microalbuminuria whose blood pressure was not controlled by telmisartan 40 mg/amlodipine 2.5 mg

<table>
<thead>
<tr>
<th>Study</th>
<th>Duration, week</th>
<th>Regimen*, mg/day</th>
<th>No</th>
<th>DBP controla, %</th>
<th>DBP responseb, %</th>
<th>SBP responsec, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Telmisartan plus</td>
<td>34</td>
<td>T40/A5</td>
<td>553</td>
<td>91.1</td>
<td>91.1</td>
<td>88.6</td>
</tr>
<tr>
<td>T80/A5</td>
<td>206</td>
<td>77.7</td>
<td>83.0</td>
<td>86.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T80/A5 + Add-on*</td>
<td>25</td>
<td>76.0</td>
<td>76.0</td>
<td>72.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Long-term follow-up71</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T80/A5 + Add-on*</td>
<td>181</td>
<td>46.4</td>
<td>59.7</td>
<td>70.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Telmisartan plus</td>
<td>34</td>
<td>T40/A10</td>
<td>216</td>
<td>93.1</td>
<td>93.1</td>
<td>88.0</td>
</tr>
<tr>
<td>T80/A10</td>
<td>436</td>
<td>92.2</td>
<td>92.9</td>
<td>92.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>amloidipine study-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>amloidipine 10 mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T80/A10 (upptitrated)*</td>
<td>91</td>
<td>79.1</td>
<td>78.0</td>
<td>82.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Long-term follow-up71</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T40-80/A10 + Add-on*</td>
<td>92</td>
<td>76.1</td>
<td>79.3</td>
<td>75.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trial no 1235.1669</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T40/A5</td>
<td>211</td>
<td>92.8</td>
<td>98.6</td>
<td>97.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T80/A5</td>
<td>48</td>
<td>66.7</td>
<td>87.5</td>
<td>93.8</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes: *Excluded if SBP ≥ 180 mmHg and/or DBP ≥ 120 mmHg; †DBP control = DBP < 90 mmHg; ‡DBP response = DBP < 90 mmHg or a DBP decrease of ≥10 mmHg; ‡‡SBP response = SBP < 140 mmHg or a SBP decrease of ≥15 mmHg; ††subjects whose BP was not controlled were given additional antihypertensive medications; ‡‡‡subjects in the T40/A10 arm whose BP was not controlled were uptitrated to T80/A10.

Abbreviations: T, telmisartan; A, amlodipine; BP, blood pressure; DBP, mean sitting diastolic blood pressure; SBP, mean sitting systolic blood pressure.

Of concern with the data presented by the original and extended TEAMSTA studies is the very low representation of blacks; of the approximately 1800 participants in the long-term studies, only 16 were black.71 As hypertension is especially prevalent in black communities, with data from 2007–2010 showing African–American men and women having high rates of occurrence (40.5% and 43.3%, respectively) and uncontrolled hypertension in those receiving treatment (71.5% and 51.0%, respectively),80 the alarming lack of data in this population highlights the need for further short- and long-term studies to validate the efficacy and safety of telmisartan/amlodipine in blacks or Hispanics (although the unpublished ClinicalTrials.gov study NCT01181011 did include ten women among the 28 participants). Telmisartan clearance is reduced in women, resulting in twofold to threefold higher plasma concentrations and a greater systolic BP response than is observed in men,81 and furthermore the pharmacokinetic profile of telmisartan alone or in combination with amlodipine in blacks or Hispanics has, to our knowledge, not been reported. In women, it is not
clear whether this greater drug exposure is also associated with a concurrent rise in AE incidence nor is it clear what effect coadministration with amlodipine may have on telmisartan pharmacokinetics (and vice versa) in women and certain minority populations.

**Additional long-term clinical trials for telmisartan/amlodipine combination therapy**

At the time of this publication, trials were underway or were of unclear status to further evaluate the long-term safety and efficacy of telmisartan/amlodipine therapy that may help expand the data available for underrepresented groups. Among the studies in progress are two actively recruiting trials and a third ongoing but not recruiting participants; these studies range from 26 weeks to 4 years. The trial of longest project duration, a phase IV study in which over 13,500 patients were randomized to evaluate the effect of low-dose telmisartan plus amlodipine versus amlodipine plus diuretics, aims to prospectively compare treatment regimens on hard clinical endpoints of stroke, MI, and death from CVD. This trial, from which some data have been
published, did not utilize single pill telmisartan/amlodipine but rather used separate pills concurrently and hence was not included in prior sections of this review. However, 48-week and 96-week results showed that both arms were similar in their reduction of BP and control rates.\(^{65,88}\) Notably, AEs were mild to moderate, occurring in \(<18\%\) at 48 weeks; peripheral edema, which was one of the more common AEs, occurred infrequently over 96 weeks (24 patients in the diuretic arm and 17 patients in the telmisartan arm).

A second long-term study (ClinicalTrials.gov identifier NCT01353274) featuring the telmisartan/amlodipine combination pill is currently ongoing but no longer recruiting. In this study, an estimated 1200 patients will be followed for a year as part of a postmarketing surveillance endeavor designed to assess the long-term safety of the single pill telmisartan/amlodipine combination in Japanese subjects. A specific safety concern to be addressed by this study is the safety of the drug in patients with hepatic disorders, an issue being scrutinized due to the significant elevations of plasma telmisartan concentrations (3–4.5 fold) in these patients. Results of this study may become available as soon as mid-2013.

A 24-week efficacy trial in 2000 (projected) participants receiving telmisartan/amlodipine is underway with a primary endpoint of mean BP change (ClinicalTrials.gov identifier NCT01316419). In this study, additional endpoints include questionnaire-based quality of life assessment and additional risk factor changes during the course of the intervention. Results are expected in 2014.

Finally, there is a single-center 26-week study dubbed “TEAMSTAProtect” (ClinicalTrials.gov identifier NCT01180205) that was designed to evaluate and compare the effects of telmisartan/amlodipine versus olmesartan and HCTZ on flow-mediated dilation, a surrogate measure for vascular health. The effects of telmisartan/amlodipine versus olmesartan and HCTZ on flow-mediated dilation, a surrogate measure for vascular health.

Additional long-term benefits that have yet to be fully elucidated. Additional long-term data in hypertensive women and minorities may be warranted to further confirm the safety and efficacy of the telmisartan/amlodipine combination pill in these populations.

**Conclusion**

Available clinical trial data suggest that the telmisartan/amlodipine combination pill is a safe efficacious option for the long-term treatment of hypertension. The complementary mechanisms of its components appear to enhance the effectiveness beyond that provided by each drug alone, including potential synergistic effects on endothelial function, while reducing some of the negative effects produced by amlodipine, such as peripheral edema. Furthermore, the potential effect(s) of telmisartan on the cardioprotective ACE2-ang (1-7)-Mas receptor axis may provide added benefits that have yet to be fully elucidated. Additional long-term data in hypertensive women and minorities may be warranted to further confirm the safety and efficacy of the telmisartan/amlodipine combination pill in these populations.

**Acknowledgments**

The authors thank Dr Christine Billecke, PhD, for her review and editorial suggestions for this manuscript.

**Disclosure**

The authors have nothing to disclose.

**References**


53. TWYNSTA (telmisartan and amlodipine besylate) [package insert]. Ingelheim, Germany: Boehringer Ingelheim; 2011.


